Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.32 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4572964 | 0.80 | GLA (0.38) | NLRP3PIM1RAB9AALDH1A1LMNA | |
| SCHEMBL4572963 | 0.80 | GLA (0.38) | NLRP3PIM1RAB9AALDH1A1LMNA | |
| SCHEMBL2522174 | 0.78 | HCAR2 (0.48) | NLRP3PIM1RAB9A | |
| SCHEMBL2522171 | 0.78 | HCAR2 (0.48) | NLRP3PIM1RAB9A | |
| SCHEMBL6297811 | 0.76 | PIK3CD (0.37) | NLRP3PIM1RAB9ACYP19A1 | |
| SCHEMBL6297810 | 0.76 | PIK3CD (0.37) | NLRP3PIM1RAB9ACYP19A1 | |
| SCHEMBL9255626 | 0.76 | KMT2A (0.49) | CCNCCDK8NLRP3RAB9AALDH1A1 | |
| SCHEMBL9255628 | 0.76 | KMT2A (0.49) | CCNCCDK8NLRP3RAB9AALDH1A1 | |
| SCHEMBL3164680 | 0.70 | HCAR2 (0.62) | RAB9AALDH1A1LMNAMAPT | |
| SCHEMBL1556671 | 0.70 | PFKFB3 (0.53) | ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1922309-B1 | N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | IL YANG PHARM CO LTD (KR) | 2014-05-21 | — | — | EP | disclosed |
| US-7501424-B2 | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | IL-YANG PHARM. CO., LTD. (KR) | 2009-03-10 | — | — | US | disclosed |
| US-20080096899-A1 | N-Phenyl-2-Pyrimidine-Amine Derivatives and Process for the Preparation Thereof | IL-YANG PHARM. CO., LTD. (KR) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096899-A1 | N-Phenyl-2-Pyrimidine-Amine Derivatives and Process for the Preparation Thereof | ITPA, TYMP, THPO | CCNC 560/4885CDK8 1739/4885NR4A2 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.